Please Login to participate

Course HomeCourse Progress
  • Pre-Test
  • Access Webcast
  • Post-Test
  • Evaluation
  • Certificate

Optimal Management Strategies for Urothelial Carcinoma


Andrea B. Apolo, MD
Senior Investigator, Genitourinary Malignancies Branch
NIH National Cancer Institute, Center for Cancer Research
Bethesda, Maryland

Alison Birtle, MD, FRCP, FRCR
Consultant Clinical Oncologist and Honorary Clinical Professor
Rosemere, Cancer Centre, Lancashire Teaching Hospitals
Preston, England

Bishoy M. Faltas, MD
Director, Bladder Cancer Research, Englander Institute for Precision Medicine
Assistant Professor of Medicine, Cell and Developmental Biology
Weill Cornell Medicine
New York, New York

Petros Grivas, MD, PhD
Associate Professor, Division of Oncology, Dept. of Medicine
University of Washington School of Medicine
Seattle, Washington

Shilpa Gupta, MD
Member, Developmental Therapeutics Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Jean H. Hoffman-Censits, MD
Co-leader, Women’s Bladder Cancer Program; Assistant Professor of Oncology
Greenberg Bladder Cancer Institute; Johns Hopkins Medicine
Baltimore, Maryland

Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine–Oncology
Stanford University School of Medicine
Stanford, California

Peter H. O’Donnell, MD
Associate Professor of Medicine
University of Chicago Medicine
Chicago, Illinois

Guru Sonpavde, MD
Bladder Cancer Director, Associate Professor of Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts



Provided by HMP Education, an HMP Global Company.

For questions regarding this educational activity, or to cancel your account, please call 609-371-1137 or email


This activity is designed for community and academic clinicians who treat or are interested in treating patients with GU malignancies, including community oncologists and other healthcare professionals (physicians-in-training, oncology nurses, pharmacists, NPs, PAs, and others) involved in the care of patients with GU cancers.


After participating in this activity, learners should be better able to:

  • Summarize techniques for screening and diagnosis of UC
  • Assess clinical efficacy and safety data for current and emerging agents to inform treatment selection and sequencing
  • Implement patient-centered care and multidisciplinary care strategies to address disparities in access to care and improve patient outcomes


This on-demand webcast is available with synchronized slides and video/audio.

To be eligible for credit, participants must complete the educational activity, complete the 5-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: December 21, 2022
Expiration Date: December 21, 2023
Estimated Time to Complete: 2.75 hour

There is no fee associated with this activity.


The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. 


Joint Accreditation with commendation logoIn support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


HMP Education designates this internet live/enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-22-254-H01-P) has been approved for a maximum of 2.75 contact hours (.275 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


This continuing nursing education internet enduring activity awards 2.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.75 contact hours. 


American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.


AAPA logoHMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 2.75 AAPA Category 1 credits. Approval is valid until December 31, 2023. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

All relevant financial relationships have been mitigated.


The faculty has reported the following:

Andrea B. Apolo has no relevant disclosures

Alison Birtle: Advisory Board - BMS, Hoffman La-Roche, Merck, Pfizer; Consultant - Pfizer

Bishoy M. Faltas: Advisory Board - Eli Lilly and Company, Immunomedics, Merck & Co., Inc., Seattle Genetics; Other Financial Support - Urotoday

Petros Grivas: Advisory Board/Consultant - Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Mirati Therapeutics, Exelixis, Roche, Genentech, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen Pharma, Gilead Sciences; Grant/Research Support - Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, Kure It Cancer Research, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics

Shilpa Gupta: Consultant - AbbVie, AstraZeneca, Array BioPharma, Bayer, BMS, Genentech, EMD Serono, Incyte, Ipsen, Janssen, Loxo Oncology, Merck, Natera, Pfizer, Seattle Genetics, Takeda; Speakers Bureau - Array BioPharma, Bayer, BMS, Genentech, Incyte, Ipsen, Janssen, Merck, Pfizer, Seattle Genetics

Jean H. Hoffman-Censits: Other Financial Support, Research Support - AbbVie, Genentech, Sanofi, GSK, UCB; Consultant - AstraZeneca, Foundation Medicine, Genentech/Roche, Seattle Genetics, Amgen, Eli Lilly, Five Prime, Merck, BMS, Taiho, Astellas, Gritstone, Pieris, Daiichi Sankyo, Zymeworks, QED, Foundation Medicine, Tempus, Guardant Health, Archer, Natera, Uro-gen

Ali Raza Khaki: Grant/Research Support - Natera, Tempus Health

Peter H. O’Donnell: Advisory Board – Astellas, curio science, EMD Serono, Genentech/Roche, Health Advances, Merck, Pfizer, SeaGen, IntrinsiQ Specialty Solutions, Janssen; Consultant – Atheneum, Axiom Healthcare, Strategies, CLD, Dedham Group, Health Advances, Merck, SeaGen; DSMB, Other Financial or Material Support – Dragonfly, G1 Therapeutics, Nektar Therapeutics; Grant/Research Support - Acerta Pharma, AstraZeneca/MedImmune, Boehriner Ingelheim, Bristol Meyers Squibb, EMD Serono, Genentech/Roche, Merck, SeaGen

Guru Sonpavde: Advisory Board – Exelixis, Genentech, Janssen Pharmaceuticals, Merck; Consultant – AstraZenaca, Bicycle, BMS, EMD Serono, G1 Therapeutics, Immunomedics/Gilead, Infinity Therapeutics, Loxo Oncology/Lilly, Merck, Pfizer Inc, Scholar Rock, Seattle Genetics, Inc.; Grant/Research Support – AstraZenaca, BMS, Immunomedics/Gilead, Janssen Pharmaceuticals, Predicine Genomics, QED Therapeutics Inc, Sanofi US; Data safety monitoring committee - Mereo Therapeutics; Other Financial or Material Support – AstraZenaca, BMS, Elsevier, Mereo Therapeutics, Myriad




Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

HMP Education planners and staff include Kelly Jackson; Kayli McGovern; Samantha Joy; Randy Robbin, CHCP; and Andrea Zimmerman, EdD.

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).


HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity needs accommodations, please call 609-371-1137.


HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Joy, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Joy will review the grievance and respond within 30 days of receiving the complaint.


Supported by an independent educational grant from Astellas and Seagen Inc.